TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02269124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aid
Description: The subject will wear a hearing aid at all times for a 3-month period. At school, he/she will wear this hearing aid in addition to using conventional measures (FM system and preferential seating).
Study: NCT03392935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1540 nanometer Erbium glass laser
Description: Subjects will receive laser treatment by dermatologist at week 0 and week 4.
Study: NCT04149834

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Group A (Test): Patients will receive NIPSA
Description: patients received Non- incised papilla surgical approache

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group B (Control): Patients will receive M-MIST
Description: patients received Modified Minimally Invasive Surgical Technique
Study: NCT04602416

Intervention type: BEHAVIORAL
Intervention: Training sessions

Intervention type: BEHAVIORAL
Intervention: Training sessions

Intervention type: BEHAVIORAL
Intervention: Training sessions

Intervention type: BEHAVIORAL
Intervention: Training sessions
Study: NCT01184261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral intervention
Description: 8 session behavioral intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral intervention
Description: 8 session behavioral intervention.
Study: NCT03776864

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: Given PO
Study: NCT03284177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium (13C)Carbonate
Description: C13-CAC breath test containing Calcium (13C) Carbonate was performed twice under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gastric acid inhibitors
Description: Gastric acid inhibitor was orally administrated once daily for 4weeks after first C13-CAC breath test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gastric pH monitoring
Description: Gastric pH monitoring was performed once under fasting condition.
Study: NCT04392323

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: COVID-19 PCR and Serology
Description: PCR for COVID entails obtaining a nasopharyngeal swab (a cotton tip introduced via the nose to obtain a sample) to determine whether there is active viral replication and viral shedding. They will then have a second test with serology and PCR for COVID-19 infection 12-16 days after discharge from the hospital. Serology implies that a blood sample will be obtained by venipuncture. A volume of 50 ml (about 4 tablespoons) or less of blood will be obtained.
Study: NCT00860808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM-101
Description: Triple intratympanic injection (one on each day 1, 2, and 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM-101
Description: Triple intratympanic injection (one on each day 1, 2, and 3)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AM-101
Description: Triple intratympanic injection (one on each day 1, 2, and 3)
Study: NCT02903914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB001158
Description: Arginase Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB001158
Description: Arginase Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB001158
Description: Arginase Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB001158
Description: Arginase Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB001158
Description: Arginase Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB001158
Description: Arginase Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB001158
Description: Arginase Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB001158
Description: Arginase Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: PD-1 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: PD-1 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: PD-1 Inhibitor
Study: NCT02348476

Intervention type: OTHER
Intervention: No Intervention
Description: No study drug is administered in this study.
Study: NCT01526499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel and Cyclophosphamide (TC)
Description: Docetaxel 75mg/m2 IVGTT D1 Cyclophosphamide 50mg PO D1-21;every 21days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel (T)
Description: Docetaxel 75mg/m2 IVGTT D1;every 21days
Study: NCT04103216

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide with Lactobacillus Reuteri DSM 17938
Description: Nitazoxanide with probiotics

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nitazoxanide
Description: Nitazoxanide with placebo
Study: NCT03047941

Intervention type: DIAGNOSTIC_TEST
Intervention: Determination of optimal cutoff values.
Description: The results of the four scores will be compared with the results of the polysomnography (PSG). A statistical analysis will be performed to determine the optimal cutoff value of each of the four scores to detect severe OSA patient with hypoxemia.
Study: NCT03446872

Intervention type: DRUG
Intervention: ONIVYDE
Description: irinotecan liposome injection

Intervention type: DRUG
Intervention: 5-fluorouracil
Description: a nucleoside metabolic inhibitor

Intervention type: DRUG
Intervention: Leucovorin
Description: an active metabolite of folic acid
Study: NCT05595655

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Motivational Interviewing
Description: Motivational Interviewing (MI) is a directive client-centred counselling approach for eliciting behavioral change by helping people to explore and resolve ambivalence. MI considers several critical factors to improving self-care in patients with HF and is based on brief interventions, which are feasible in several healthcare settings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational Interviewing (MI) is a directive client-centred counselling approach for eliciting behavioral change by helping people to explore and resolve ambivalence. MI considers several critical factors to improving self-care in patients with HF and is based on brief interventions, which are feasible in several healthcare settings.
Study: NCT05033197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBBS intervention
Description: The CBBS intervention group received the 16-week intervention, including 16 CBBS lessons in basketball unit (two 40-minute lessons/week, 8 weeks) and 16 CBBS lessons in soccer unit (two 40-minute lessons/week, 8 weeks) during the 2018-2019 school year.
Study: NCT02787928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal hydromorphone
Description: Intrathecal hydromorphone will be administered in an up/down dosage fashion. A successful dose will be defined as a patient not requiring additional narcotic pain medication outside of the standard VCU order set, which includes PRN oxycodone 5 and 10 mg every 4 hours and a one time PRN 1 mg hydromorphone IV. Failure of a dose will be if patient requires additional narcotic pain medication outside of these parameters
Study: NCT02481154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG881
Description: AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression or development of other unacceptable toxicity
Study: NCT03617172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol 100Mcg Tab
Description: Two 100mcg capsules twice per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules twice per day
Study: NCT00738998

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaires about pain and other symptoms, quality of life, and ability to work will be completed.
Study: NCT04160520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Description: Establish proof of concept that low dose morphine in combination with pramipexole is non-inferior to standard dose morphine with respect to providing analgesia in patients presenting to the ED with pain associated with renal colic.
Study: NCT00738998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone Calls
Description: A telephone system will call every 2 weeks so that you can rate your symptoms and how they interfere with daily activities. Each call will take about 5 minutes.
Study: NCT01387217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2018682
Description: GSK2018682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2018682
Description: GSK2018682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched Placebo
Study: NCT03351842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cis Platinum/Carboplatin, Pemetrexed Disodium
Description: Intravenous inject Pemetrexed Disodium for Injection over 10 minutes, waiting for at least 30 minutes, then followed by cis Platinum/ Carboplatin over 2 hours

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Undergo surgery
Description: Therapeutic conventional surgery, R0 resection
Study: NCT04160520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Establish proof of concept that low dose morphine in combination with pramipexole is non-inferior to standard dose morphine with respect to providing analgesia in patients presenting to the ED with pain associated with renal colic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Establish proof of concept that low dose morphine in combination with pramipexole is non-inferior to standard dose morphine with respect to providing analgesia in patients presenting to the ED with pain associated with renal colic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral tablet
Description: Establish proof of concept that low dose morphine in combination with pramipexole is non-inferior to standard dose morphine with respect to providing analgesia in patients presenting to the ED with pain associated with renal colic.
Study: NCT02799901

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Injection of nivolumab
Study: NCT03351842

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Undergo surgery
Description: Therapeutic conventional surgery, R0 resection
Study: NCT01889667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORMD-0801 Dose # 1
Description: Oral Insulin Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORMD-0801 Dose # 2
Description: Oral Insulin Formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oil Capsules
Study: NCT01285141

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CN54gp140 glycoprotein-hsp70 conjugate vaccine
Description: CN54gp140-hsp70 conjugate vaccine administered intravaginally 3 times over a 12-week period
Study: NCT00095693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Description: Correlative studies
Study: NCT01387828

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic splenic aneurysm repair, eventual splenectomy
Description: Aneurysmectomy and eventual artery reconstruction or splenectomy performed with a laparoscopic approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparotomic splenic artery aneurysm repair, eventual artery reconstruction or splenectomy
Description: Aneurysmectomy and eventual artery reconstruction or splenectomy performed with a laparotomic approach
Study: NCT03469752

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent education classes
Description: 8 weekly classes for fathers and youth (10-14 years) at community centers focused on improving parenting skills, youth energy balance related behaviors and weight status
Study: NCT01394055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RM-131
Description: 100 μg subcutaneously once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo volume subcutaneously once
Study: NCT02990026

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Specialty Mental Health Probation
Description: Specialty mental health probation includes the following components: (1) exclusively mentally ill caseload of probationers; (2) reduced caseload of 40-45 probationers; (3) problem-solving supervision orientation; (4) ongoing training and consultation; and (5) greater connection with local mental health services

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specialty Mental Health Probation
Description: Specialty mental health probation includes the following components: (1) exclusively mentally ill caseload of probationers; (2) reduced caseload of 40-45 probationers; (3) problem-solving supervision orientation; (4) ongoing training and consultation; and (5) greater connection with local mental health services
Study: NCT03407898

Intervention type: OTHER
Intervention: intubation time
Description: intubation attempt number and intubation time

Intervention type: OTHER
Intervention: intubation time
Description: intubation attempt number and intubation time
Study: NCT02757989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transplantation
Description: allogeneic hematopoietic stem cell transplantation in patients with donor
Study: NCT02608944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: Adenosine: 0.14mg/kg/min for 6 min. IV injection for MRI perfusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: Regadenoson: 0.4mg in 5ml, given as a rapid (10 seconds) IV injection for MRI perfusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O-15 labeled radioactive water
Description: O-15 labeled radioactive water: Up to 50mCi IV injection at rest and again at hyperemia for PET Imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Pass dynamic contrast enhanced MRI scans will be performed at rest and during hyperemia caused by either adenosine infusion or regadenoson

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET Imaging
Description: Quantitative PET imaging with O-15 labeled radioactive water will be given at a different day.
Study: NCT01469221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apaziquone
Description: 6 weekly multi-instillation of Apaziquone 4 mg in 40 mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 weekly multi-instillation of matching placebo in 40mL
Study: NCT01150526

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CaHMB
Description: CaHMB capsules with each capsule containing 0.8 g of HMB

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CaHMB
Description: CaHMB capsules with each capsule containing 0.8 g of HMB

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB Free Acid Gel
Description: HMB Free acid in a gel form with each dose supplying 0.8 g of HMB free acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB Free Acid Gel
Description: HMB Free acid in a gel form with each dose supplying 0.8 g of HMB free acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules similar in size and color to the CaHMB capsules used in the study

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules similar in size and color to the CaHMB capsules used in the study

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules similar in size and color to the CaHMB capsules used in the study

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules similar in size and color to the CaHMB capsules used in the study

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo Gel Dosage
Description: A corn syrup based placebo with flavoring and taste similar to the HMB Free Acid Gel

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo Gel Dosage
Description: A corn syrup based placebo with flavoring and taste similar to the HMB Free Acid Gel

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo Gel Dosage
Description: A corn syrup based placebo with flavoring and taste similar to the HMB Free Acid Gel

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel Dosage
Description: A corn syrup based placebo with flavoring and taste similar to the HMB Free Acid Gel
Study: NCT01370902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0141-0000-0100
Description: Single dose administered subcutaneously (under the skin), up to six dose levels. Progression to next dose will be based on safety evaluation. Initiation of the MD s.c. phase will depend on the results from the SD i.v. cohorts as well as the first two dose cohorts of the SD s.c. part

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single dose administered subcutaneously (under the skin) as a comparator at all dose levels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0141-0000-0100
Description: Multiple doses administered subcutaneously (under the skin) at 4 different occasions with a dosing interval of two weeks, at five different dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Multiple doses administered subcutaneously (under the skin) as a comparator at all dose levels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0141-0000-0100
Description: Single dose administered intravenously (into a vein), up to nine dose levels. Progression to next dose will be based on safety evaluation. Initiation of the SD s.c. phase will depend on the results from the first three dose cohorts of the SD i.v. part

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single dose administered intravenously (into a vein), as a comparator at all dose levels
Study: NCT03582215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: Cream
Description: Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: Lotion
Description: Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: Spray 1
Description: Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: Spray 2
Description: Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: Lotion
Description: Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: Aerosol Spray
Description: Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: Nonaerosol Spray
Description: Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: Pump Spray
Description: Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
Study: NCT02140047

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-Low + DPT-IPV
Description: 0.25mL, subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-High + DPT-IPV
Description: 0.5mL, subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Haemophilus influenza type b conjugate vaccine + DPT-IPV
Description: 0.5mL, subcutaneous injection
Study: NCT00380237

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)
Description: Live attenuated H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine
Study: NCT00572377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FemLife Gel
Description: the gel or placebo (240 mcg)applied to the vagina; 20 doses to be used over the 30 day period and to complete the Female Sexual Encounter Profile (FSEP).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the gel or placebo (240 mcg) applied to the vagina; 20 doses to be used over the 30 day period and to complete the Female Sexual Encounter Profile (FSEP).
Study: NCT03961334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: 150mg 2x/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: 5mg 2x/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: 60mg 1x/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 100mg 1x/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 75mg 1x/d